Condition: Advanced Solid Tumor · Sponsor: Oncomatryx Biopharma S.L.
Open-label, two parallel arm, multicenter, Phase 1 dose-escalation study to evaluate the safety and tolerability of OMTX705, both as monotherapy or in combination with pembrolizumab (Part 1) or tislelizumab (Part 2) in the treatment of patients with advanced or metastatic cancer in whom there is no available standard therapeutic option.
This description comes directly from the study's public registry record.
Ignacio García-Ribas, MD · +34 946 08 70 37 · igarcia@oncomatryx.com
Susana Román · +34 946 08 70 37 · sroman@oncomatryx.com
Always discuss trial participation with your own doctor first.
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
| Hospital Universitari Vall d'Hebron | Barcelona, Barcelona, Spain | Not Yet Recruiting |
| ICO L'Hospitalet | L'Hospitalet de Llobregat, Barcelona, Spain | Recruiting |
| Hospital Clínico Universitario de Santiago | Santiago de Compostela, Galicia, Spain | Not Yet Recruiting |
| Hospital Universitario de Donostia | San Sebastián, Guipúzcoa, Spain | Recruiting |
| Hospital 12 Octubre | Madrid, Madrid, Spain | Recruiting |
| Hospital MD Anderson | Madrid, Madrid, Spain | Recruiting |
| Clínica Universitaria de Navarra | Pamplona, Navarre, Spain | Recruiting |
| Onkologikoa | San Sebastián, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05547321